Skip to main content
Erschienen in: Trials 1/2016

Open Access 01.12.2016 | Erratum

Erratum to: ‘Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial’

verfasst von: Thomas P. Hellyer, Niall H. Anderson, Jennie Parker, Paul Dark, Tina Van Den Broeck, Suveer Singh, Ronan McMullan, Ashley M. Agus, Lydia M. Emerson, Bronagh Blackwood, Savita Gossain, Tim S. Walsh, Gavin D. Perkins, Andrew Conway Morris, Daniel F. McAuley, A. John Simpson

Erschienen in: Trials | Ausgabe 1/2016

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found under doi:10.​1186/​s13063-016-1442-x.

Erratum

Unfortunately, the original version of this article [1] contained an error. There are two references in the text to the threshold for defining VAP as greater than 10^4 colony forming units/ml. These should read greater OR EQUAL to 10^4 colony forming units/ml. The error is in the abstract and in the intervention sections.
In the abstract, please replace:
Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at [>]104 colony forming units per millilitre (CFU/ml).
With the following correct version:
Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at [≥]104 colony forming units per millilitre (CFU/ml).
In the Interventions, please replace:
VAP is confirmed by the widely used threshold of growth of a potential pathogen at [>]104 colony forming units per ml (CFU/ml)(13).
With the following correct version:
VAP is confirmed by the widely used threshold of growth of a potential pathogen at [≥]104 colony forming units per ml (CFU/ml)(13).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Hellyer TP, Anderson NH, Jennie P, Paul D, Tina Van Den B, Suveer S, Ronan MM, Agus AM, Emerson LM, Bronagh B, Savita G, Walsh TS, Perkins GD, Conway Morris A, McAuley DF, Simpson AJ. Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial. Trials. 2016;17:318.CrossRefPubMedPubMedCentral Hellyer TP, Anderson NH, Jennie P, Paul D, Tina Van Den B, Suveer S, Ronan MM, Agus AM, Emerson LM, Bronagh B, Savita G, Walsh TS, Perkins GD, Conway Morris A, McAuley DF, Simpson AJ. Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial. Trials. 2016;17:318.CrossRefPubMedPubMedCentral
Metadaten
Titel
Erratum to: ‘Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial’
verfasst von
Thomas P. Hellyer
Niall H. Anderson
Jennie Parker
Paul Dark
Tina Van Den Broeck
Suveer Singh
Ronan McMullan
Ashley M. Agus
Lydia M. Emerson
Bronagh Blackwood
Savita Gossain
Tim S. Walsh
Gavin D. Perkins
Andrew Conway Morris
Daniel F. McAuley
A. John Simpson
Publikationsdatum
01.12.2016
Verlag
BioMed Central
Erschienen in
Trials / Ausgabe 1/2016
Elektronische ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-016-1594-8

Weitere Artikel der Ausgabe 1/2016

Trials 1/2016 Zur Ausgabe